<DOC>
	<DOCNO>NCT02943720</DOCNO>
	<brief_summary>A multicentre , Double-blind , Placebo-Controlled , Randomized Trial Assess Efficacy Tolerability Two Dosing Regimens AllerT , Combination Contiguous Overlapping Peptides Derived Bet v 1 , Adults Birch Pollen Allergic Rhinitis/Rhinoconjunctivitis</brief_summary>
	<brief_title>ATIBAR - Efficacy Safety Two Doses AllerT Patients Allergic Birch Pollen</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>Adult subject 18 65 yr old , male female moderate severe allergic Rhinitis/Rhinoconjunctivitis birch pollen two precede birch pollen season positive Skin Prick Test ( SPT ) birch pollen extract positive specific IgE CAP Bet v1 . persistent noncontrolled asthma ( Forced Expiratory Volume , FEV1 &lt; 85 % predict ) , previous specific immunotherapy ( SIT ) tree pollen , previous SIT allergen within 5 year , previous history severe anaphylactic reaction , perennial allergic Rhinitis/Rhinoconjunctivitis , disorder possibly influence trial outcome , pregnancy , severely debilitate disease , primary secondary immunodeficiency treatment immunosuppressor drug within one month prior randomization ( oral steroid , immunosuppressor ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>